tradingkey.logo
tradingkey.logo
Search

Nautilus Biotechnology Inc

NAUT
Add to Watchlist
0.955USD
-0.011-1.14%
Close 09-21 16:00ET
121.50MMarket Cap
LossP/E TTM

More Details of Nautilus Biotechnology Inc Company

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Nautilus Biotechnology Inc Profile

Ticker SymbolNAUT
Company nameNautilus Biotechnology Inc
IPO dateAug 07, 2020
CEOPatel (Sujal)
Number of employees155
Security typeOrdinary Share
Fiscal year-endAug 07
Address2701 Eastlake Ave East
CitySEATTLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98102
Phone12063332001
Websitehttps://www.nautilus.bio/
Ticker SymbolNAUT
IPO dateAug 07, 2020
CEOPatel (Sujal)

Company Executives of Nautilus Biotechnology Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--

FAQs

Who are the top five shareholders of Nautilus Biotechnology Inc?

The top five shareholders of Nautilus Biotechnology Inc are: Dr. Parag Mallick

How many institutions hold shares of Nautilus Biotechnology Inc (NAUT)?

As of 2026Q1, 180 institutions hold shares of Nautilus Biotechnology Inc, with a combined market value of approximately 60.30M, accounting for 47.66% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1539418.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.